Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UNLOCKING LEGALITIES: Challenges And Surprises In The EU Medtech Reg Reform

This article was originally published in SRA

Executive Summary

The texts of the new EU medical device and IVD regulations have now been published in their likely final versions, save for the tweaking expected during the European Commission's legal review. Scrip Regulatory Affairs sister publication Clinica asked Erik Vollebregt, partner at Axon Lawyers, what the most significant challenges will be now for the whole of the medtech sector, and where the biggest surprises lie.

You may also be interested in...



EU TTIP Device Proposals Rely Heavily on Device Regulators Forum

The European Commission circulated its device-regulation proposals as part of negotiations for the Transatlantic Trade and Investment Partnership with the US. It emphasized convergence of technical and clinical requirements and the important role of the International Medical Device Regulators Forum.

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT040827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel